HealthCare Global Enterprises Limited’s board has approved its financial results for the quarter and nine months ending December 31, 2025. Additionally, they’ve introduced the HCG Employee Stock Option Scheme, 2026, subject to shareholder and regulatory approvals. Dr. Naveen R. Nagar has been appointed as Head – Clinical Strategy, and Mr. Pankaj Gautam as Chief Information Officer, both designated as Senior Management Personnel.
Financial Performance Approved
HealthCare Global Enterprises (HCG) has announced the approval of its unaudited financial results for Q3 2026, encompassing both standalone and consolidated figures. These results cover the quarter and nine-month period that ended on December 31, 2025.
Introduction of ESOP Scheme
The board has greenlit the HCG Employee Stock Option Scheme, 2026 (HCG ESOS 2026). This scheme allows the company to grant stock options to eligible employees within HCG and its subsidiaries. Implementation is contingent upon securing the necessary approvals from shareholders and regulatory bodies. The maximum number of shares that can be issued under the HCG ESOS 2026 is 74,21,455.
Leadership Appointments
Several key leadership changes have been announced:
- Dr. Naveen R. Nagar: Appointed as Head – Clinical Strategy.
- Mr. Pankaj Gautam: Appointed as Chief Information Officer.
Both individuals will hold the designation of Senior Management Personnel within the company.
Key Financial Highlights (Standalone)
The following are key figures from the standalone financial results:
- Revenue from operations: ₹34,056 lakhs for Q3 2026, ₹101,090 lakhs for the nine-month period.
- Profit before tax: ₹1,460 lakhs.
- Profit for the period: ₹1,078 lakhs.
Basic earnings per share stood at ₹0.77.
Key Financial Highlights (Consolidated)
The following are key figures from the consolidated financial results:
- Revenue from operations: ₹63,118 lakhs for Q3 2026, ₹188,814 lakhs for the nine-month period.
Source: BSE
